Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • skannan4
    Junior Member
    • Sep 2017
    • 5

    Handling pseudogenes in RNA-seq

    I recently performed an RNA-seq experiment that was mapped using STAR through a package called zUMIs. Typically, our reads are 66 bp (and in the past our experiments have been mapped to the human genome) but this time our data ended up being 50 bp reads to the mouse genome. Our final counts dataset seems to be dominated by pseudogenes; close to 25% of the UMIs are linked to pseudogenes.

    Of course, while pseudogenes can be transcribed, in our case it seems more likely that we have had an issue from the mapping front (I'm guessing due to the shorter read length). From our biological context, we certainly don't expect a massive number of transcribed pseudogenes. My question is - is there any way to coalesce the counts between genes and their corresponding pseudogenes (without remapping)? And if there isn't a good way to handle this, what STAR settings should we try adjusting to map to further promote mapping to canonical genes over pseudogenes?

    Thanks!

Latest Articles

Collapse

  • SEQadmin2
    Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
    by SEQadmin2


    Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

    The systematic characterization of the human proteome has
    ...
    07-20-2026, 11:48 AM
  • SEQadmin2
    Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
    by SEQadmin2



    Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
    ...
    07-09-2026, 11:10 AM
  • SEQadmin2
    Cancer Drug Resistance: The Lingering Barrier to Rising Survival
    by SEQadmin2



    Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

    There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
    07-08-2026, 05:17 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, 07-20-2026, 11:10 AM
0 responses
18 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-13-2026, 10:26 AM
0 responses
32 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-09-2026, 10:04 AM
0 responses
43 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-08-2026, 10:08 AM
0 responses
29 views
0 reactions
Last Post SEQadmin2  
Working...